search
Back to results

Traumatic Brain Injury Peripheral Nerve Study (TBI)

Primary Purpose

Traumatic Brain Injury

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Eon-mini IPG (implantable pulse generator)
Eon-mini IPG (implantable pulse generator)
Eon-mini IPG (implantable pulse generator)
Sponsored by
Abbott Medical Devices
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Traumatic Brain Injury focused on measuring Traumatic Brain Injury

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subjects able to provide informed consent to participate in the study;
  2. Subjects between the ages of 18 and 65;
  3. Subjects with clear evidence and/or documentation of mild traumatic brain injury as defined by the American Congress on Rehabilitation Medicine (1993):

    • Closed head injury/trauma
    • Score of 13-15 on the Glasgow Coma Scale
    • Documented/witnessed loss of consciousness < 30 minutes post injury
    • Post traumatic amnesia less than 24 hours post injury.
  4. Subjects 12 month post-injury with DSM IV diagnosis of Postconcussive Disorder Research Criteria (see Appendix A for detailed definition):

    • Evidence from neuropsychological testing of difficulty in attention or memory
    • Complaints, at baseline, of three or more postconcussive symptoms that have been present at least 3 months.
  5. Subject medication that is TBI-related has remained stable for at least 4 weeks prior to baseline data collection;
  6. Current medical options have been tried and documented without sufficient improvement in symptom control;
  7. Subject agrees not to add or increase any medication throughout the randomization period of the study;
  8. Subject is willing to cooperate with the study requirements.

Exclusion Criteria:

  1. Subject diagnosed with a terminal disease (ie. cancer, leukemia, or advanced stages of disease resulting in less than 12 months life expectancy);
  2. Subject currently participating in another clinical study;
  3. Subject with demand-type cardiac pacemakers, an infusion pump or any implantable device (ie. deep brain stimulators, spinal cord stimulators, CSF shunts, aneurism clip and cochlear implants) which may interfere with therapy;
  4. Subject with significant depression and/or other significant psychiatric/behavioral problems likely to interfere with study completion or result in addition distress to the subject as determined by a qualified Psychiatrist or psychologist;
  5. Subject with an existing medical condition that is likely to require repetitive MRI evaluation in the future (ie. epilepsy, stroke, acoustic neuroma, tumor);
  6. Subject with a history of open head trauma;
  7. Subject with visual, hearing or motor deficits that impair ability to complete neurocognitive testing;
  8. Subject with a history of moderate to severe TBI;
  9. Subject with post traumatic seizure disorder;
  10. Subject with history of learning disability and/or ADHD
  11. Subject with history of chronic headache syndrome prior to post-concussive disorder;
  12. Subject is not willing to maintain current TBI-related medication regimen;
  13. Female candidates of child bearing potential who are pregnant (confirmed by positive urine/blood pregnancy test), not using adequate contraception (ie. oral contraceptives, injectibles, implants, patches, condoms, barrier methods, spermicides, intrauterine devices, and sterilization), or nursing (lactating) a child.

Sites / Locations

  • Kevin Yoo, MD/Palomar Neurosurgery Ctr

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Low frequency

High frequency

No stimulation

Arm Description

Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.

Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.

Programming parameters will be set to the lowest possible level and minimal power will be generated. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.

Outcomes

Primary Outcome Measures

Reduction in persistent cognitive impairments

Secondary Outcome Measures

Full Information

First Posted
February 15, 2012
Last Updated
February 1, 2019
Sponsor
Abbott Medical Devices
search

1. Study Identification

Unique Protocol Identification Number
NCT01588691
Brief Title
Traumatic Brain Injury Peripheral Nerve Study
Acronym
TBI
Official Title
A Feasibility Study to Examine the Efficacy of C2-C3 Dermatomal Peripheral Nerve Stimulation in Cognitive Improvements Following Persistent Impairment After Traumatic Brain Injury
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
December 2011 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
November 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abbott Medical Devices

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Peripheral nerve stimulation for the treatment of sequelae due to traumatic brain injury. This study will specifically examine patients with mild traumatic brain injury (TBI) who have persistent cognitive impairments lasting one year or longer. Neuropsychological testing will occur to confirm the diagnosis.
Detailed Description
The subject will complete participation in three groups evaluating different programming parameters. After surgery, each subject will be randomized to Group A or Group B. Group C will be completed in the middle followed by the alternate A/B Group. Crossover will occur at 3 week intervals until subjects complete all three groups. During this period, all subjects will receive a subject programmer that will only enable them to activate the "on and off" positions and adjust amplitude within the prescribed range. After subjects have completed the three pre-defined groups they will select the most effective and comfortable setting continuation of the study. The pulse width and frequency parameters will be set to the optimal settings identified by the subject. Amplitude will be set at a level that produces comfortable paresthesia for the subject. Subjects will return to the clinic for programming changes post system internalization at 3 weeks, 6 weeks, and 9 weeks. Subjects will receive a PET scan at the 3 and 9 week visit. Additional follow-up evaluations will occur at 12 weeks, 18 weeks, and 24 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Traumatic Brain Injury
Keywords
Traumatic Brain Injury

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
3 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Low frequency
Arm Type
Active Comparator
Arm Description
Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
Arm Title
High frequency
Arm Type
Active Comparator
Arm Description
Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
Arm Title
No stimulation
Arm Type
Placebo Comparator
Arm Description
Programming parameters will be set to the lowest possible level and minimal power will be generated. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
Intervention Type
Device
Intervention Name(s)
Eon-mini IPG (implantable pulse generator)
Intervention Description
programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.
Intervention Type
Device
Intervention Name(s)
Eon-mini IPG (implantable pulse generator)
Intervention Description
programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.
Intervention Type
Device
Intervention Name(s)
Eon-mini IPG (implantable pulse generator)
Intervention Description
programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
Primary Outcome Measure Information:
Title
Reduction in persistent cognitive impairments
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects able to provide informed consent to participate in the study; Subjects between the ages of 18 and 65; Subjects with clear evidence and/or documentation of mild traumatic brain injury as defined by the American Congress on Rehabilitation Medicine (1993): Closed head injury/trauma Score of 13-15 on the Glasgow Coma Scale Documented/witnessed loss of consciousness < 30 minutes post injury Post traumatic amnesia less than 24 hours post injury. Subjects 12 month post-injury with DSM IV diagnosis of Postconcussive Disorder Research Criteria (see Appendix A for detailed definition): Evidence from neuropsychological testing of difficulty in attention or memory Complaints, at baseline, of three or more postconcussive symptoms that have been present at least 3 months. Subject medication that is TBI-related has remained stable for at least 4 weeks prior to baseline data collection; Current medical options have been tried and documented without sufficient improvement in symptom control; Subject agrees not to add or increase any medication throughout the randomization period of the study; Subject is willing to cooperate with the study requirements. Exclusion Criteria: Subject diagnosed with a terminal disease (ie. cancer, leukemia, or advanced stages of disease resulting in less than 12 months life expectancy); Subject currently participating in another clinical study; Subject with demand-type cardiac pacemakers, an infusion pump or any implantable device (ie. deep brain stimulators, spinal cord stimulators, CSF shunts, aneurism clip and cochlear implants) which may interfere with therapy; Subject with significant depression and/or other significant psychiatric/behavioral problems likely to interfere with study completion or result in addition distress to the subject as determined by a qualified Psychiatrist or psychologist; Subject with an existing medical condition that is likely to require repetitive MRI evaluation in the future (ie. epilepsy, stroke, acoustic neuroma, tumor); Subject with a history of open head trauma; Subject with visual, hearing or motor deficits that impair ability to complete neurocognitive testing; Subject with a history of moderate to severe TBI; Subject with post traumatic seizure disorder; Subject with history of learning disability and/or ADHD Subject with history of chronic headache syndrome prior to post-concussive disorder; Subject is not willing to maintain current TBI-related medication regimen; Female candidates of child bearing potential who are pregnant (confirmed by positive urine/blood pregnancy test), not using adequate contraception (ie. oral contraceptives, injectibles, implants, patches, condoms, barrier methods, spermicides, intrauterine devices, and sterilization), or nursing (lactating) a child.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roni Diaz
Organizational Affiliation
Abbott Medical Devices
Official's Role
Study Director
Facility Information:
Facility Name
Kevin Yoo, MD/Palomar Neurosurgery Ctr
City
Poway
State/Province
California
ZIP/Postal Code
92064
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Traumatic Brain Injury Peripheral Nerve Study

We'll reach out to this number within 24 hrs